Clinical trial
Self-administration of Subcutaneous Elranatamab in the Patients' Homes. An Open Label, Phase Two, Prospective, Multi-center, Non-randomized, Sponsor-initiated Explorative Trial
NCT06015542 is registered in ClinicalTrials.gov with Thomas Lund as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Self-administration of Subcutaneous Elranatamab in the Patients' Homes. An Open Label, Phase Two, Prospective, Multi-center, Non-randomized, Sponsor-initiated Explorative Trial
- Lead sponsor
- Thomas Lund
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- January 29, 2025
- Completion date
- July 1, 2027
- Enrollment
- 20 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.